Novartis AG (NVS)
| Previous Close | 84.67 |
| Open | 84.55 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 84.37 - 84.92 |
| 52 Week Range | 77.04 - 98.52 |
| Volume | 1,500,696 |
| Avg. Volume | 1,930,142 |
| Market Cap | 189.944B |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | 21.52 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.20 (3.77%) |
| Ex-Dividend Date | Mar. 04, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)1Potentially clinically meaningful improvements in both PFS and OS were observed among pre-specified subgroups of patients with inflammatory biomarkers; additional analyses are ongoing1Results support continued study of canakinumab i
- GlobeNewswire
Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care Facilitated by Novartis, Invisible Nation will aim to reduce and ultimately prevent many of the 15 million1 ASCVD deaths each year and dramatically lower what is estimated to become $1 trillion in annual CV disease care cost by 20302Network members will engage policymakers, healthcare syste
- GlobeNewswire
Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotic
